Ypsomed Holding AG
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable inje… Read more
Ypsomed Holding AG (YPHDF) - Net Assets
Latest net assets as of September 2025: $807.19 Million USD
Based on the latest financial reports, Ypsomed Holding AG (YPHDF) has net assets worth $807.19 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.21 Billion) and total liabilities ($401.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $807.19 Million |
| % of Total Assets | 66.78% |
| Annual Growth Rate | 8.9% |
| 5-Year Change | 68.18% |
| 10-Year Change | 153.77% |
| Growth Volatility | 595.01 |
Ypsomed Holding AG - Net Assets Trend (2002–2025)
This chart illustrates how Ypsomed Holding AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ypsomed Holding AG (2002–2025)
The table below shows the annual net assets of Ypsomed Holding AG from 2002 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $679.68 Million | +10.03% |
| 2024-03-31 | $617.73 Million | +8.32% |
| 2023-03-31 | $570.31 Million | +42.48% |
| 2022-03-31 | $400.28 Million | -0.96% |
| 2021-03-31 | $404.14 Million | +4.88% |
| 2020-03-31 | $385.35 Million | +1.73% |
| 2019-03-31 | $378.80 Million | +10.91% |
| 2018-03-31 | $341.54 Million | +13.17% |
| 2017-03-31 | $301.80 Million | +12.68% |
| 2016-03-31 | $267.84 Million | +11.30% |
| 2015-03-31 | $240.64 Million | +5.47% |
| 2014-03-31 | $228.16 Million | +4.96% |
| 2013-03-31 | $217.37 Million | -0.29% |
| 2012-03-31 | $218.00 Million | -59.48% |
| 2011-03-31 | $538.06 Million | +0.06% |
| 2010-03-31 | $537.74 Million | +23.04% |
| 2009-03-31 | $437.03 Million | +4.66% |
| 2008-03-31 | $417.58 Million | +7.06% |
| 2007-03-31 | $390.03 Million | -3.46% |
| 2006-03-31 | $404.01 Million | +13.11% |
| 2005-03-31 | $357.17 Million | +2916.66% |
| 2004-03-31 | $11.84 Million | -89.40% |
| 2003-03-31 | $111.68 Million | +16.85% |
| 2002-03-31 | $95.58 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ypsomed Holding AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 11083.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $645.93 Million | 95.03% |
| Common Stock | $193.14 Million | 28.42% |
| Total Equity | $679.68 Million | 100.00% |
Ypsomed Holding AG Competitors by Market Cap
The table below lists competitors of Ypsomed Holding AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shandong Shida Shenghua Chem
SHG:603026
|
$1.40 Billion |
|
Fulltech Fiber Glass
TWO:1815
|
$1.40 Billion |
|
The Boston Beer Company Inc
F:BBEA
|
$1.40 Billion |
|
Enlight Renewable Energy Ltd. Ordinary Shares
NASDAQ:ENLT
|
$1.40 Billion |
|
National Bank Holdings Corporation
NYSE:NBHC
|
$1.40 Billion |
|
Liaoning Cheng Da Co Ltd
SHG:600739
|
$1.40 Billion |
|
Spirent Communications plc
PINK:SPNUF
|
$1.40 Billion |
|
Zhuhai CosMX Battery Co Ltd
SHG:688772
|
$1.40 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ypsomed Holding AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 617,734,000 to 679,685,000, a change of 61,951,000 (10.0%).
- Net income of 87,504,000 contributed positively to equity growth.
- Dividend payments of 27,299,000 reduced retained earnings.
- Share repurchases of 2,534,000 reduced equity.
- New share issuances of 1,081,000 increased equity.
- Other comprehensive income decreased equity by 166,297,000.
- Other factors increased equity by 169,496,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $87.50 Million | +12.87% |
| Dividends Paid | $27.30 Million | -4.02% |
| Share Repurchases | $2.53 Million | -0.37% |
| Share Issuances | $1.08 Million | +0.16% |
| Other Comprehensive Income | $-166.30 Million | -24.47% |
| Other Changes | $169.50 Million | +24.94% |
| Total Change | $- | 10.03% |
Book Value vs Market Value Analysis
This analysis compares Ypsomed Holding AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.28x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 42.75x to 7.28x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-03-31 | $8.47 | $362.28 | x |
| 2003-03-31 | $44.55 | $362.28 | x |
| 2004-03-31 | $4.74 | $362.28 | x |
| 2005-03-31 | $31.67 | $362.28 | x |
| 2006-03-31 | $35.84 | $362.28 | x |
| 2007-03-31 | $34.63 | $362.28 | x |
| 2008-03-31 | $37.06 | $362.28 | x |
| 2009-03-31 | $38.82 | $362.28 | x |
| 2010-03-31 | $44.77 | $362.28 | x |
| 2011-03-31 | $42.50 | $362.28 | x |
| 2012-03-31 | $17.23 | $362.28 | x |
| 2013-03-31 | $17.18 | $362.28 | x |
| 2014-03-31 | $18.09 | $362.28 | x |
| 2015-03-31 | $19.06 | $362.28 | x |
| 2016-03-31 | $21.21 | $362.28 | x |
| 2017-03-31 | $23.93 | $362.28 | x |
| 2018-03-31 | $27.14 | $362.28 | x |
| 2019-03-31 | $30.06 | $362.28 | x |
| 2020-03-31 | $29.87 | $362.28 | x |
| 2021-03-31 | $31.25 | $362.28 | x |
| 2022-03-31 | $30.95 | $362.28 | x |
| 2023-03-31 | $41.91 | $362.28 | x |
| 2024-03-31 | $45.25 | $362.28 | x |
| 2025-03-31 | $49.78 | $362.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ypsomed Holding AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.87%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.68%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 1.96x
- Recent ROE (12.87%) is above the historical average (11.62%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 6.04% | 5.74% | 0.86x | 1.23x | $-3.78 Million |
| 2003 | 10.80% | 8.79% | 0.96x | 1.28x | $892.70K |
| 2004 | 97.89% | 6.25% | 0.37x | 42.30x | $10.41 Million |
| 2005 | 10.97% | 16.21% | 0.37x | 1.84x | $3.48 Million |
| 2006 | 13.77% | 17.92% | 0.47x | 1.65x | $15.25 Million |
| 2007 | 0.70% | 0.99% | 0.45x | 1.60x | $-36.26 Million |
| 2008 | 6.37% | 9.25% | 0.45x | 1.53x | $-15.17 Million |
| 2009 | 5.99% | 9.60% | 0.43x | 1.45x | $-17.54 Million |
| 2010 | 1.75% | 3.71% | 0.38x | 1.23x | $-44.35 Million |
| 2011 | 0.97% | 2.15% | 0.36x | 1.25x | $-48.60 Million |
| 2012 | 3.90% | 3.42% | 0.76x | 1.50x | $-13.30 Million |
| 2013 | 0.76% | 0.67% | 0.72x | 1.57x | $-20.09 Million |
| 2014 | 5.96% | 4.93% | 0.78x | 1.55x | $-9.21 Million |
| 2015 | 8.06% | 6.33% | 0.85x | 1.50x | $-4.67 Million |
| 2016 | 13.37% | 10.63% | 0.87x | 1.45x | $9.03 Million |
| 2017 | 15.32% | 11.87% | 0.92x | 1.40x | $16.07 Million |
| 2018 | 15.24% | 11.17% | 0.93x | 1.46x | $17.91 Million |
| 2019 | 15.88% | 13.25% | 0.77x | 1.55x | $22.26 Million |
| 2020 | 3.11% | 2.98% | 0.58x | 1.80x | $-26.03 Million |
| 2021 | 1.47% | 1.44% | 0.56x | 1.82x | $-33.73 Million |
| 2022 | 5.89% | 4.97% | 0.61x | 1.93x | $-16.15 Million |
| 2023 | 9.12% | 10.31% | 0.58x | 1.53x | $-4.96 Million |
| 2024 | 12.69% | 14.29% | 0.50x | 1.78x | $16.59 Million |
| 2025 | 12.87% | 11.68% | 0.56x | 1.96x | $19.54 Million |
Industry Comparison
This section compares Ypsomed Holding AG's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,683,526,542
- Average return on equity (ROE) among peers: -32.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ypsomed Holding AG (YPHDF) | $807.19 Million | 6.04% | 0.50x | $1.40 Billion |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $480.24 Million | 2.52% | 0.41x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $19.68 Billion | 1.70% | 0.48x | $37.82 Billion |
| Align Technology Inc (ALGN) | $3.85 Billion | 10.94% | 0.61x | $11.75 Billion |
| AngioDynamics Inc (ANGO) | $355.71 Million | 3.06% | 0.15x | $354.40 Million |
| Ansell Limited (ANSLF) | $386.33 Million | -0.45% | 0.87x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $8.27 Billion |
| AtriCure Inc (ATRC) | $72.60 Million | -15.79% | 0.54x | $1.42 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $9.03 Million | -338.35% | 0.77x | $156.14 Million |